COVID-19, HHV6 and MOG antibody: A perfect storm

BACKGROUND: Serious neurological complications of SARS-CoV-2 are increasingly being recognized. CASE: We report a novel case of HHV6 myelitis with parainfectious MOG-IgG in the setting of COVID-19-induced lymphopenia and hypogammaglobulinemia. The patient experienced complete neurological recovery w...

Descripción completa

Detalles Bibliográficos
Autores principales: Jumah, Muruj, Rahman, Farah, Figgie, Mark, Prasad, Ankita, Zampino, Anthony, Fadhil, Ali, Palmer, Kaitlin, Buerki, Robin Arthur, Gunzler, Steven, Gundelly, Praveen, Abboud, Hesham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879032/
https://www.ncbi.nlm.nih.gov/pubmed/33607505
http://dx.doi.org/10.1016/j.jneuroim.2021.577521
Descripción
Sumario:BACKGROUND: Serious neurological complications of SARS-CoV-2 are increasingly being recognized. CASE: We report a novel case of HHV6 myelitis with parainfectious MOG-IgG in the setting of COVID-19-induced lymphopenia and hypogammaglobulinemia. The patient experienced complete neurological recovery with gancyclovir, high dose corticosteroids, and plasma exchange. To our knowledge, this is the first case of HHV6 reactivation in the central nervous system in the setting of COVID19 infection and the first case of MOG-IgG myelitis in the setting of SARS-CoV-2 and HHV6 coinfection. CONCLUSION: Patients with neurological manifestations in the setting of COVID19-related immunodeficiency should be tested for opportunistic infections including HHV6. Viral infection is a known trigger for MOG-IgG and therefore this antibody should be checked in patients with SARS-CoV-2 associated demyelination.

Ejemplares similares